These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31243506)

  • 1. [Personalized treatment of Parkinson's disease].
    Brockmann K; Gasser T
    Nervenarzt; 2019 Aug; 90(8):767-772. PubMed ID: 31243506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
    George S; Brundin P
    J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?
    Pozo Devoto VM; Falzone TL
    Dis Model Mech; 2017 Sep; 10(9):1075-1087. PubMed ID: 28883016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
    Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
    Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting α-synuclein: Therapeutic options.
    Dehay B; Decressac M; Bourdenx M; Guadagnino I; Fernagut PO; Tamburrino A; Bassil F; Meissner WG; Bezard E
    Mov Disord; 2016 Jun; 31(6):882-8. PubMed ID: 26926119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Disease-Modifying Therapy for Parkinson's Disease].
    Shimura H; Hattori N
    Brain Nerve; 2017 Feb; 69(2):159-165. PubMed ID: 28202824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic approaches to target alpha-synuclein pathology.
    Brundin P; Dave KD; Kordower JH
    Exp Neurol; 2017 Dec; 298(Pt B):225-235. PubMed ID: 28987463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.
    Tolmasov M; Djaldetti R; Lev N; Gilgun-Sherki Y
    Expert Rev Neurother; 2016 May; 16(5):505-13. PubMed ID: 26959397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Wong YC; Krainc D
    Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic approaches in Parkinson's disease and related disorders.
    Valera E; Masliah E
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):346-352. PubMed ID: 26749150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.
    Vekrellis K; Stefanis L
    Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of rodent models in advancing precision medicine for Parkinson's disease.
    Simons E; Fleming SM
    Handb Clin Neurol; 2023; 193():3-16. PubMed ID: 36803818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.
    Henrich MT; Geibl FF; Lee B; Chiu WH; Koprich JB; Brotchie JM; Timmermann L; Decher N; Matschke LA; Oertel WH
    Acta Neuropathol Commun; 2018 May; 6(1):39. PubMed ID: 29747690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activating Autophagy as a Therapeutic Strategy for Parkinson's Disease.
    Fowler AJ; Moussa CE
    CNS Drugs; 2018 Jan; 32(1):1-11. PubMed ID: 29492779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
    Lang AE; Espay AJ
    Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease.
    Stojkovska I; Krainc D; Mazzulli JR
    Cell Tissue Res; 2018 Jul; 373(1):51-60. PubMed ID: 29064079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New therapy approaches for Parkinson's disease].
    Brockmann K; Berg D
    Nervenarzt; 2017 Apr; 88(4):391-396. PubMed ID: 28289790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification.
    Ko WKD; Bezard E
    Exp Neurol; 2017 Dec; 298(Pt B):172-179. PubMed ID: 28764902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.